Nasdaq:US$16.68 (-0.98) | HKEX:HK$26.65 (+0.00) | AIM:£2.69 (-0.19)
Search Result
Previous Article   |   Next Article
Announcements & Press Releases, Oncology / Immunology | 29 Feb 2008

Chi-Med Announces Start of Patient Enrolment in a Global Phase IIb Ulcerative Colitis Clinical Trial of HMPL-004, its Leading Anti-Inflammatory Drug Candidate

1 items
a080229